A randomised controlled crossover pilot study of meropenem standard 30 minute infusion versus prolonged 3 hour infusion in intensive care patients

A study of intensive care patients comparing meropenem 500mg 3 hour infusion versus 1g 30 minute infusion and time above mean inhibitory concentration

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612000284864

Enrollment

Registered

2012-03-12

Start date

2009-05-16

Completion date

Unknown

Last updated

2026-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Meropenem is an antibiotic used in the treatment of serious infections. This study aims to investigate whether giving meropenem a by a longer infusion (3 hours) but a lower dose, enables the antibiotic to be in the bloodstream for at least the same amount of time as a higher dose given over a short time (30 minutes).

Interventions

Meropenem 500mg administered as a 3 hour infusion. Wash-out period between treatments of at least 24 hours.

Study design

Allocation

Randomised controlled trial

Intervention model

Crossover

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Healthy volunteers

Inclusion criteria

Adult intensive care patients Sepsis Predicted duration of treatment more than 3 days

Exclusion criteria

Predicted duration of treatment < 3 days Hypersensitivity to meropenem or other beta-lactams

Outcome results